It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Researchers at Beijing's Chinese Academy of Sciences have used the gene-editing technology CRISPR to create mice from two ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. Marvai, a San Diego company, said Tuesday that the acquisition would expand the ...